CYP2E1 and hepatocellular carcinoma: The most notable difference between the two groups was the Vmax of CYP2E1, which was increased by 2.3-fold in HCC patients relative to controls (1238.0 vs. 539.3 pmol/min/mg, respectively; P < 0.01).